[Recent trend on the development of new anticancer drugs].
More than 35 candidate drugs have been under their clinical studies in Japan currently. These include antimetabolites, drugs originated from natural products, miscellaneous compounds and hormones. Since the time of appearance of cisplatin and taxol, we found the possibility to discover new active drugs against human solid cancers. Our recent clinical studies on topoisomerase inhibitors and microtubules inhibitors have also been proving the clinical usefulness of these drugs for cancer treatment. From now on, we have to think the drug development from ethical aspects, improving quality of life and prolonging the survival of the treated patients. For these purposes, we have to be careful to choose candidate drugs for their clinical trials.
Tsukagoshi
S
S
Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo.
D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents / Q000494:pharmacology; D003561:Cytarabine / Q000031:analogs & derivatives; D005544:Forecasting; D008727:Methotrexate / Q000031:analogs & derivatives; D008870:Microtubules / Q000187:drug effects; D013629:Tamoxifen
D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D003561:Cytarabine; D013629:Tamoxifen; D008727:Methotrexate